[Dacarbacinum (DTIC) and bronchogenic carcinoma (author's transl)].
A pilot study is reported on the results achieved with the cytostatic agent dacarbacinum (DTIC) on previously untreated, inoperable bronchogenic carcinomas which had been histologically and/or cytologically verified. Altogether there were 16 patients, i.e. 13 males and 3 females. DTIC monotherapy was administered to 14 patients; one patient received additionally vitamin A in high dosage and a further patient VP 16 (a podophyllotoxin preparation). The achieved results (a remission rate of 50%) justify the further application of this agent, whereby its relatively limited side effects as well as goood tolerability in elderly patients (over 70 years of age) are emphasized. The inclusion of the preparation in effective combinations is discussed.
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D003606:Dacarbazine / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011013:Pneumonectomy; D014226:Triazenes / Q000627:therapeutic use*; D014801:Vitamin A / Q000008:administration & dosage / Q000627:therapeutic use
D014226:Triazenes; D014801:Vitamin A; D003606:Dacarbazine
Dacarbacinum (DTIC) beim Lungenkarzinom.